Home > Insider Trading > Filing (0001415889-25-006608)

Filing Details

Accession Number:: 0001415889-25-006608
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2025-03-04 17:20:38
Reporting Period:: 2025-03-01

Filing Date:: 2025-03-04
Accepted Time:: 2025-03-04 17:20:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1597264	Blueprint Medicines Corp	BPMC	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1769740	Ariel Hurley	C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139	Principal Accounting Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2025-03-01	6,506	$0.00	21,473	No	4	A	Direct
Common Stock	Disposition	2025-03-03	775	$89.63	20,698	No	4	S	Direct
Common Stock	Disposition	2025-03-03	238	$90.92	20,460	No	4	S	Direct
Common Stock	Disposition	2025-03-03	631	$92.00	19,829	No	4	S	Direct
Common Stock	Disposition	2025-03-03	484	$93.42	19,345	No	4	S	Direct
Common Stock	Disposition	2025-03-03	1,075	$95.16	18,270	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2025-03-01	7,007	$95.67	7,007	$96.57

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
7,007		2035-02-28	No	4	A	Direct

Footnotes

The reported transaction involved the Reporting Person's receipt of a grant of 6,506 restricted stock units under the Issuer's 2024 Stock Incentive Plan.
Effected pursuant to a trading plan adopted on September 12, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported is an average sale price. The shares were sold in multiple transactions ranging from $89.34 to $90.14. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is an average sale price. The shares were sold in multiple transactions ranging from $90.36 to $91.21. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is an average sale price. The shares were sold in multiple transactions ranging from $91.45 to $92.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is an average sale price. The shares were sold in multiple transactions ranging from $93.03 to $93.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported is an average sale price. The shares were sold in multiple transactions ranging from $95.15 to $95.36. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter.